NCT03577041Recruiting
Medico-economic Evaluation of Anti-VEGF Treatments in the Treatment of naïve Age-related Macular Degeneration (AMD): a Model Adapted to the French Context
Source: ClinicalTrials.gov · Last updated 15 Jun 2026
Brief summary (registry, in English)
Age-related macular degeneration (AMD) is the leading cause of blindness after 50 years in industrialized countries, compromising daily activities and reducing quality of life. And whose treatment is one of the first health expenditures. Since September 2015, Bevacizumab, which does not have marketing authorization in AMD, has been given a temporary recommendation for use. Studies in other countries have shown that bevacizumab is cost-effective in the treatment of AMD compared to other anti-VEGF therapies used.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 600 (estimated)
- First submitted
- 4 Jun 2018
- Start date
- 29 Jan 2020
- Primary completion date
- Jun 2026
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Diseases
- Macular degeneration
- NCT number
- NCT03577041
What you commit to
- Study type: Observational
- Planned participants: 600
- From 29 Jan 2020 to the primary completion date, Jun 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous or current treatment of AMD by intravenous injection of anti-VEGF or surgery dating less than 2 months in the studied eye,
- Contraindications to the taking of Bevacizumab or Ranibizumab or Aflibercept,
Other illness
- Known hypersensitivity to pharmaceutical agents used,
- Severe active intraocular inflammation, or history autoimmune or idiopathic uveitis,
- Active or suspected ocular or periocular infection,
Lab values
- Glycated hemoglobin greater than 12%,
Other
- Aphakia in the studied eye,
- Fibrosis or retrofoveolar retinal atrophy of the eye studied,
- Tearing of the pigment epithelium reaching my macula of the studied eye,
- Choroidal neovascularization unrelated to AMD,
- Diabetic retinopathy and / or diabetic maculopathy proven,
- Pregnant or lactating women,
- Intraocular pressure\> 25mmHg despite two hypotonizing treatments in eye drops,
- Patient under tutorship or curatorship or private public law.
Who the study is looking for
- Naive neovascular AMD form of retro localization foveal, unilateral or bilateral (one eye per patient will be studied),
- Patients to be treated with intravitreous injections of Bevacizumab or Ranibizumab or Aflibercept,
- Patient using effective contraception if he is of childbearing age
- Patient informed and not having made his opposition to the research,
- Patient under social security scheme.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Amiens Coordinator of this site? Confirm its status | Amiens | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.